BR112013001753A2 - método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada. - Google Patents
método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.Info
- Publication number
- BR112013001753A2 BR112013001753A2 BR112013001753A BR112013001753A BR112013001753A2 BR 112013001753 A2 BR112013001753 A2 BR 112013001753A2 BR 112013001753 A BR112013001753 A BR 112013001753A BR 112013001753 A BR112013001753 A BR 112013001753A BR 112013001753 A2 BR112013001753 A2 BR 112013001753A2
- Authority
- BR
- Brazil
- Prior art keywords
- iaip
- plasma
- treating
- disease
- preparing
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 3
- 230000004064 dysfunction Effects 0.000 title abstract 3
- 102000012479 Serine Proteases Human genes 0.000 title abstract 2
- 108010022999 Serine Proteases Proteins 0.000 title abstract 2
- 208000035475 disorder Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 108010093564 inter-alpha-inhibitor Proteins 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Analytical Chemistry (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36733110P | 2010-07-23 | 2010-07-23 | |
| PCT/US2011/045099 WO2012012773A1 (en) | 2010-07-23 | 2011-07-22 | Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013001753A2 true BR112013001753A2 (pt) | 2016-05-31 |
Family
ID=44534634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013001753A BR112013001753A2 (pt) | 2010-07-23 | 2011-07-22 | método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8841248B2 (enExample) |
| EP (1) | EP2596014B1 (enExample) |
| JP (1) | JP5830096B2 (enExample) |
| KR (1) | KR20130093607A (enExample) |
| CN (1) | CN103119058A (enExample) |
| AU (1) | AU2011280907B2 (enExample) |
| BR (1) | BR112013001753A2 (enExample) |
| CA (1) | CA2806645A1 (enExample) |
| CO (1) | CO6680653A2 (enExample) |
| EA (1) | EA201390156A1 (enExample) |
| ES (1) | ES2717177T3 (enExample) |
| MX (1) | MX2013000958A (enExample) |
| SG (1) | SG187599A1 (enExample) |
| WO (1) | WO2012012773A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005046587A2 (en) | 2003-11-08 | 2005-05-26 | Prothera Biologics | Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use |
| EP2291654B1 (en) | 2008-05-28 | 2018-04-11 | Prothera Biologics, Inc. | Preparation and composition of inter-alpha inhibitor proteins from blood |
| WO2011150284A2 (en) | 2010-05-26 | 2011-12-01 | Baxter International Inc. | Removal of serine proteases by treatment with finely divided silicon dioxide |
| AU2010202125B1 (en) | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
| BR112013001753A2 (pt) | 2010-07-23 | 2016-05-31 | Baxter Healthcare Sa | método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada. |
| TWI629283B (zh) | 2012-02-23 | 2018-07-11 | 巴克斯歐塔公司 | 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱 |
| CA2885604A1 (en) | 2012-09-09 | 2014-03-13 | Prothera Biologics, Inc. | Treatment of ischemia using inter-alpha inhibitor proteins |
| US20140206844A1 (en) * | 2013-01-18 | 2014-07-24 | Prothera Biologics | Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material |
| US20170232079A1 (en) * | 2015-10-06 | 2017-08-17 | Kieu Hoang | Method of manufacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv |
| EP3512539A4 (en) | 2016-09-13 | 2020-07-29 | Prothera Biologics, Inc. | METHODS FOR TREATING LUNG DISEASE USING INTER-ALPHA INHIBITOR PROTEINS |
| US20200057077A1 (en) | 2017-04-25 | 2020-02-20 | Prothera Biologics, Inc. | Methods for quantifying inter-alpha inhibitor proteins |
| SG11202003793WA (en) | 2017-10-30 | 2020-05-28 | Baxalta GmbH | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| WO2020086879A1 (en) * | 2018-10-24 | 2020-04-30 | Prothera Biologics, Inc. | Inter-alpha inhibitor proteins and methods of use thereof |
| CN109867717A (zh) * | 2019-04-01 | 2019-06-11 | 山西瑞亚力生物技术有限公司 | 一种血浆中α1微球蛋白的提取方法 |
| CN114096558B (zh) * | 2019-07-04 | 2024-10-01 | 德国杰特贝林生物制品有限公司 | 纯化c1-inh的方法 |
| WO2021202373A1 (en) * | 2020-03-31 | 2021-10-07 | Baxalta Incorporated | A method to produce an immunoglobulin preparation from c-1 inhibitor depleted plasma |
| CN116322920A (zh) * | 2020-11-09 | 2023-06-23 | 武田药品工业株式会社 | 使用氧化硅吸附从血浆中纯化fviii |
| CA3198925A1 (en) | 2020-11-16 | 2022-05-19 | Yow-Pin Lim | Methods for purifying inter-alpha inhibitor proteins |
| EP4518875A1 (en) * | 2022-05-02 | 2025-03-12 | Takeda Pharmaceutical Company Limited | Methods of preparing cohn pool concentrate from blood plasma through ultrafiltration |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2390074A (en) * | 1942-02-09 | 1945-12-04 | Research Corp | Protein product and process |
| DK166763C (da) | 1983-03-16 | 1993-07-12 | Immuno Ag | Immunoglobulin-g-holdig fraktion |
| US5055447A (en) * | 1988-07-28 | 1991-10-08 | Genentech, Inc. | Method and compositions for the treatment and prevention of septic shock |
| US5177194A (en) | 1990-02-01 | 1993-01-05 | Baxter International, Inc. | Process for purifying immune serum globulins |
| FR2711371B1 (fr) | 1993-10-18 | 1995-12-29 | Aetsrn | Procédé de préparation d'un concentré d'inter-alpha-trypsine inhibiteur à usage thérapeutique et concentré obtenu. |
| PT764658E (pt) * | 1995-09-22 | 2002-06-28 | Zlb Bioplasma Ag | Processo para a obtencao de imunoglobulinas a partir de fraccoes que resultam do fraccionamento do plasma sanguineo humano |
| JP2004511492A (ja) | 2000-10-13 | 2004-04-15 | オクタファルマ アクチェン ゲゼルシャフト | ビクニンを含む血漿画分、その調製方法、およびその使用 |
| WO2005046587A2 (en) * | 2003-11-08 | 2005-05-26 | Prothera Biologics | Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use |
| CN101160133B (zh) * | 2004-11-05 | 2013-01-09 | 普罗瑟拉生物公司 | 治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物 |
| EP2129686B1 (en) * | 2007-03-20 | 2016-07-13 | CSL Behring GmbH | Methods for industrial scale production of therapeutic complement factor h preparations from human plasma |
| EP2291654B1 (en) * | 2008-05-28 | 2018-04-11 | Prothera Biologics, Inc. | Preparation and composition of inter-alpha inhibitor proteins from blood |
| AT514675B1 (de) * | 2009-07-23 | 2019-05-15 | Baxalta Inc | Herstellung von faktor h (fh) und fh-derivaten aus plasma |
| AU2010202125B1 (en) * | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
| BR112013001753A2 (pt) | 2010-07-23 | 2016-05-31 | Baxter Healthcare Sa | método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada. |
-
2011
- 2011-07-22 BR BR112013001753A patent/BR112013001753A2/pt not_active Application Discontinuation
- 2011-07-22 CA CA2806645A patent/CA2806645A1/en not_active Abandoned
- 2011-07-22 AU AU2011280907A patent/AU2011280907B2/en active Active
- 2011-07-22 EP EP11749976.4A patent/EP2596014B1/en active Active
- 2011-07-22 WO PCT/US2011/045099 patent/WO2012012773A1/en not_active Ceased
- 2011-07-22 US US13/189,390 patent/US8841248B2/en active Active
- 2011-07-22 EA EA201390156A patent/EA201390156A1/ru unknown
- 2011-07-22 ES ES11749976T patent/ES2717177T3/es active Active
- 2011-07-22 KR KR1020137004453A patent/KR20130093607A/ko not_active Withdrawn
- 2011-07-22 SG SG2013005640A patent/SG187599A1/en unknown
- 2011-07-22 MX MX2013000958A patent/MX2013000958A/es not_active Application Discontinuation
- 2011-07-22 JP JP2013521858A patent/JP5830096B2/ja active Active
- 2011-07-22 CN CN2011800457670A patent/CN103119058A/zh active Pending
-
2013
- 2013-02-21 CO CO13035387A patent/CO6680653A2/es not_active Application Discontinuation
-
2014
- 2014-08-19 US US14/463,533 patent/US9505814B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103119058A (zh) | 2013-05-22 |
| EP2596014B1 (en) | 2018-11-28 |
| US9505814B2 (en) | 2016-11-29 |
| US8841248B2 (en) | 2014-09-23 |
| MX2013000958A (es) | 2013-11-20 |
| EA201390156A1 (ru) | 2014-01-30 |
| CO6680653A2 (es) | 2013-05-31 |
| AU2011280907B2 (en) | 2016-02-04 |
| ES2717177T3 (es) | 2019-06-19 |
| US20150045538A1 (en) | 2015-02-12 |
| CA2806645A1 (en) | 2012-01-26 |
| KR20130093607A (ko) | 2013-08-22 |
| WO2012012773A1 (en) | 2012-01-26 |
| AU2011280907A1 (en) | 2013-02-07 |
| JP2013535468A (ja) | 2013-09-12 |
| JP5830096B2 (ja) | 2015-12-09 |
| US20120053113A1 (en) | 2012-03-01 |
| EP2596014A1 (en) | 2013-05-29 |
| SG187599A1 (en) | 2013-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013001753A2 (pt) | método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada. | |
| TR201816379T4 (tr) | DNA-PK inhibitörleri. | |
| BRPI0909040B8 (pt) | derivados de azetidina e ciclobutano, seus usos, e composição | |
| CL2014000511A1 (es) | Compuestos derivados de quinazolina, inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7; proceso de preparacion; composiciones farmaceuticas que los contienen y el uso en el tratamiento y/o la prevencion de enfermedades tales como cancer. | |
| PH12017501501A1 (en) | Compositions and methods for inhibiting expression of tmprss6 gene | |
| BR112015009942A2 (pt) | derivados de tiofeno fundidos tricíclicos como inibidores de jak | |
| MX377845B (es) | Inhibidores de calicreína plasmática humana. | |
| UY35391A (es) | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c | |
| UY32629A (es) | Compuestos antivirales, composiciones y uso para la manufactura de un medicamento para el tratamiento de trastornos asociados con hepatitis c. | |
| BR112014003919A2 (pt) | métodos e meios para modificar um genoma de planta | |
| UY33735A (es) | Compuestos antivirales | |
| BR112013032434A2 (pt) | restauração dentária, método para sua produção e vidro cerâmico | |
| CR20140108A (es) | Compuesto de ciclopropanoamina | |
| EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
| EA201491028A8 (ru) | Способ получения замещенных 5-фтор-1н-пиразолопиридинов | |
| CL2014001838A1 (es) | Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras. | |
| WO2013040227A3 (en) | Therapeutic compounds | |
| BR112017008103A2 (pt) | composto, composição farmacêutica, métodos para tratar uma doença e uma condição, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo e de um segundo agente ativo. | |
| BR112015014367A2 (pt) | formulações inibidoras de lfa-1 | |
| BR112013030264A2 (pt) | ácidos acéticos de benzociclohepteno | |
| BR112014012459A2 (pt) | 2h-indazóis como antagonistas do receptor de ep2 | |
| BR112013026680A2 (pt) | composto, método de tratamento de uma doença inflamatória e composição farmacêutica | |
| ECSP14027694A (es) | Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido | |
| MX385687B (es) | Inhibidores de calicreína plasmática humana. | |
| GB201213484D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |